衰弱对123172例糖尿病患者临床结局的影响:基于发病年龄与药物选择的全国性10年轨迹分析
该研究纳入123172例40岁及以上新诊断糖尿病患者,按多病衰弱指数(mFI)分为健壮、轻度、中度和重度衰弱四组,分析不同发病年龄(40-64、65-74、75-84、85+岁)下衰弱与临床结局的关联。结果显示,随着诊断年龄增长,衰弱比例升高,mFI评分在10年随访期间显著增加;与健壮组相比,轻度、中度和重度衰弱与全因死亡、非计划住院、心血管病相关死亡、主要不良心血管事件(MACEs)和低血糖风险升高相关。结论建议将衰弱评估与管理纳入常规糖尿病照护。
要点
- 新诊断糖尿病患者中,衰弱比例随诊断年龄增长而升高,mFI评分在10年随访期间显著增加。
- 与健壮组相比,轻度、中度和重度衰弱均与全因死亡风险升高相关(aHR分别为1.69、2.46、3.40)。
- 非计划住院、心血管病相关死亡、MACEs和低血糖也呈现与衰弱程度相似的关联趋势。
核心结论
- 衰弱在新诊断糖尿病患者中随发病年龄增长而更常见,且与全因死亡、非计划住院、心血管病相关死亡、MACEs和低血糖风险升高相关。
- 建议将衰弱评估和管理纳入常规糖尿病照护。
研究设计与样本
- 全国性基于人群的10年轨迹分析,纳入123172例40岁及以上新诊断糖尿病患者。
- 依据多病衰弱指数(mFI)将患者分为健壮、轻度、中度和重度衰弱四个亚组。
- 采用Cox比例风险模型分析不同发病年龄(40-64、65-74、75-84、85+岁)下衰弱与临床结局的关联。
主要发现
- 随着诊断年龄增长,衰弱比例升高,且mFI评分在10年随访期间显著增加。
- 与健壮组相比,轻度衰弱全因死亡aHR为1.69(95%CI 1.60-1.80,P<0.01),中度衰弱aHR为2.46(95%CI 2.29-2.65,P<0.01),重度衰弱aHR为3.40(95%CI 3.16-3.65,P<0.01)。
- 非计划住院、心血管病相关死亡、MACEs和低血糖也呈现与衰弱程度相似的关联结果。
关键数值与推荐
- 衰弱分组依据多病衰弱指数(mFI),分为健壮、轻度、中度、重度四个亚组。
- 发病年龄分层为40-64、65-74、75-84和85+岁。
- 全因死亡风险:轻度衰弱aHR 1.69(95%CI 1.60-1.80,P<0.01),中度衰弱aHR 2.46(95%CI 2.29-2.65,P<0.01),重度衰弱aHR 3.40(95%CI 3.16-3.65,P<0.01)。
临床怎么用
- 在糖尿病常规照护中应纳入衰弱评估,尤其关注高龄发病患者。
- 根据衰弱程度分层管理,对轻度及以上衰弱患者加强监测与干预以降低死亡、住院和低血糖等风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Frailty substantially increased the risk of adverse clinical outcomes, which was also critical in diabetes management. This study aimed to investigate the interrelationships between the age of onset, frailty, anti-diabetic medications and clinical outcomes in people with diabetes mellitus (DM). METHODS: A total of 123,172 people aged 40 years and older who were newly diagnosed with DM were identified and categorised into four frailty subgroups (robust, mild, moderate and severe) based on the multimorbidity frailty index (mFI). Cox proportional hazards models were used to examine associations between frailty and clinical outcomes at different ages of DM onsets (40-64, 65-74, 75-84 and 85+ years). Outcomes of interest included generic outcomes (mortality and unplanned hospitalisation) and DM-related outcomes (cardiovascular disease-related mortality, major adverse cardiovascular events (MACEs), diabetes-related hospitalisation and hypoglycaemia). RESULTS: The proportion of frailty increased with age at diagnosis amongst people with incident DM and the mFI scores increased significantly during the 10-year follow-up. Amongst people with diabetes, those with mild, moderate and severe frailty were associated with greater risks of all-cause mortality (mild: adjusted hazard ratio (aHR) 1.69 [95% confidence interval (CI) 1.60-1.80], P < 0.01; moderate: aHR 2.46 [2.29-2.65], P < 0.01; severe frailty: aHR 3.40 [3.16-3.65], P < 0.01) compared with the robust group. Similar results were found in unplanned hospitalisations, cardiovascular disease-related mortality, MACEs and hypoglycaemia. CONCLUSIONS: Our study quantified the prevalence of frailty, captured its dynamic changes and examined its impacts on various clinical outcomes amongst people with diabetes at different ages at onset. Frailty assessment and management should be implemented into routine diabetes care.
引用
- Huang ST, Chen LK, Hsiao FY, et al. Clinical impacts of frailty on 123,172 people with diabetes mellitus considering the age of onset and drugs of choice: a nationwide population-based 10-year trajectory analysis. Age Ageing. 2023. PMID: 37505989. doi:10.1093/ageing/afad128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。